Tag Archive for: biomarkers

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

/in

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more

New paper in Frontiers in Medicine reveals first reliable biomarker test for early kidney transplant rejection detection in living-donor recipients

/in

Use of numares’ metabolite constellation showed a stable urinary metabolic profile in the first 14 days for living donor recipients, enabling accurate early rejection detection Deceased donor recipients exhibit ischemia‑driven metabolic alterations that transiently mask rejection signals Groundbreaking study was led by researchers at University Hospital Regensburg in conjunction with numares Health Regensburg, Germany, 09 […]

Read more

numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON ® LDLp Test System

/in

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysia numares Health appoints BioD Medica for local distribution MDA filing for additional CE-marked product is currently in progress   Regensburg, Germany, 16 December 2025 – numares Health (“numares”), the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, […]

Read more

Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium

/in

Consortium brings together industry, academic, and regulatory experts to advance research and bridge gaps in drug development targeting Alzheimer’s disease Asceneuron to contribute its expertise in neurodegenerative disease to advance biomarkers for drug development in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 26 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to […]

Read more